Bethany D Nugent1, Maura K McCall, Mary Connolly, Susan R Mazanec, Susan M Sereika, Catherine M Bender, Margaret Q Rosenzweig. 1. Bethany D. Nugent, PhD, RN, is Research Associate, School of Nursing, University of Pittsburgh, Pennsylvania. Maura K. McCall, MSN, RN, is Graduate Student Researcher, School of Nursing, University of Pittsburgh, Pennsylvania. Mary Connolly, BSN, RN, is Project Director, School of Nursing, University of Pittsburgh, Pennsylvania. Susan M. Sereika, PhD, is Professor, School of Nursing, University of Pittsburgh, Pennsylvania. Catherine M. Bender, PhD, RN, FAAN, is Professor, School of Nursing, University of Pittsburgh, Pennsylvania. Margaret Q. Rosenzweig, PhD, CRNP-C, AOCNP, FAAN, is Professor, School of Nursing, University of Pittsburgh, Pennsylvania. Susan R. Mazanec, PhD, RN, AOCN, is Assistant Professor, Frances Payne Bolton School of Nursing, Case Western Reserve University, Cleveland, Ohio.
Abstract
BACKGROUND: The 5-year survival for Black women with breast cancer in the United States is lower than White women for stage-matched disease. Our past and ongoing work and that of others suggest that symptom incidence, cancer-related distress, and ineffective communication contribute to racial disparity in dose reduction and early therapy termination. Although race is perhaps the most studied social determinant of health, it is clear that race alone does not account for all disparities. OBJECTIVES: The aim of the study was to present a study protocol of Black and White women prescribed breast cancer chemotherapy. The aims are to (1) examine and compare chemotherapy received/prescribed over time and in total; (2a) examine and compare symptom incidence, distress, and management and clinical encounter, including patient-centeredness of care and management experience over time and (2b) correlate symptom incidence, distress, and management experience to Aim 1; and (3) explore the effects of social determinants of health, including age, income, education, zip code, and lifetime stress exposure, on Aims 1, 2a, and 2b. METHODS: A longitudinal, repeated-measures (up to 18 time points), comparative, mixed-methods design is employed with 179 White and 179 Black women from 10 sites in Western Pennsylvania and Northeast Ohio over the course of chemotherapy and for 2 years following completion of therapy. RESULTS: The study began in January 2018, with estimated complete data collection by late 2023. DISCUSSION: This study is among the first to explore the mechanistic process for racial disparity in dosage and delay across the breast cancer chemotherapy course. It will be an important contribution to the explanatory model for breast cancer treatment disparity and may advance potential mitigation strategies for racial survival disparity.
BACKGROUND: The 5-year survival for Black women with breast cancer in the United States is lower than White women for stage-matched disease. Our past and ongoing work and that of others suggest that symptom incidence, cancer-related distress, and ineffective communication contribute to racial disparity in dose reduction and early therapy termination. Although race is perhaps the most studied social determinant of health, it is clear that race alone does not account for all disparities. OBJECTIVES: The aim of the study was to present a study protocol of Black and White women prescribed breast cancer chemotherapy. The aims are to (1) examine and compare chemotherapy received/prescribed over time and in total; (2a) examine and compare symptom incidence, distress, and management and clinical encounter, including patient-centeredness of care and management experience over time and (2b) correlate symptom incidence, distress, and management experience to Aim 1; and (3) explore the effects of social determinants of health, including age, income, education, zip code, and lifetime stress exposure, on Aims 1, 2a, and 2b. METHODS: A longitudinal, repeated-measures (up to 18 time points), comparative, mixed-methods design is employed with 179 White and 179 Black women from 10 sites in Western Pennsylvania and Northeast Ohio over the course of chemotherapy and for 2 years following completion of therapy. RESULTS: The study began in January 2018, with estimated complete data collection by late 2023. DISCUSSION: This study is among the first to explore the mechanistic process for racial disparity in dosage and delay across the breast cancer chemotherapy course. It will be an important contribution to the explanatory model for breast cancer treatment disparity and may advance potential mitigation strategies for racial survival disparity.
Authors: Melissa K Yee; Susan M Sereika; Catherine M Bender; Adam M Brufsky; Mary C Connolly; Margaret Q Rosenzweig Journal: Cancer Date: 2017-02-15 Impact factor: 6.860
Authors: Jonas A de Souza; Bonnie J Yap; Fay J Hlubocky; Kristen Wroblewski; Mark J Ratain; David Cella; Christopher K Daugherty Journal: Cancer Date: 2014-06-20 Impact factor: 6.860
Authors: Lu Zhang; Jessica King; Xiao-Cheng Wu; Mei-Chin Hsieh; Vivien W Chen; Qingzhao Yu; Elizabeth Fontham; Michelle Loch; Lori A Pollack; Tekeda Ferguson Journal: Cancer Epidemiol Date: 2018-11-08 Impact factor: 2.984
Authors: M Dodd; S Janson; N Facione; J Faucett; E S Froelicher; J Humphreys; K Lee; C Miaskowski; K Puntillo; S Rankin; D Taylor Journal: J Adv Nurs Date: 2001-03 Impact factor: 3.187
Authors: Kenneth A Wallston; Courtney Cawthon; Candace D McNaughton; Russell L Rothman; Chandra Y Osborn; Sunil Kripalani Journal: J Gen Intern Med Date: 2013-08-06 Impact factor: 5.128
Authors: Angela Fagerlin; Brian J Zikmund-Fisher; Peter A Ubel; Aleksandra Jankovic; Holly A Derry; Dylan M Smith Journal: Med Decis Making Date: 2007-07-19 Impact factor: 2.583
Authors: Jennifer J Griggs; Melony E S Sorbero; Azadeh T Stark; Susanne E Heininger; Andrew W Dick Journal: Breast Cancer Res Treat Date: 2003-09 Impact factor: 4.872
Authors: Jean Yoon; Jennifer L Malin; Diana M Tisnado; May Lin Tao; John L Adams; Martha J Timmer; Patricia A Ganz; Katherine L Kahn Journal: Breast Cancer Res Treat Date: 2007-07-19 Impact factor: 4.872